Investigating the role of Butyrophilins in colon cancer
Role of Butyrophilins in Colon Cancers Aggressiveness Evaluation
This study is trying to see if certain molecules in the body can help predict how well people with colon cancer will do after surgery.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Institut Paoli-Calmettes Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Marseille) |
| Trial ID | NCT04185272 on ClinicalTrials.gov |
What this trial studies
This study aims to quantify BTNL molecules in patients with colon cancer to determine their potential as prognostic markers. It involves analyzing the status of BTN and BTNL in patients who are undergoing surgery for non-metastatic or synchronous metastatic colon cancer. The study will include patients who have a performance status of 0 or 1 and have provided informed consent. The goal is to better understand the relationship between these molecules and cancer prognosis.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old with non-metastatic colon cancer or synchronous metastatic colon cancer eligible for combined surgery.
Not a fit: Patients with rectal cancer, colon cancer recurrence, or those who have received neoadjuvant therapy are unlikely to benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide new prognostic markers that help predict outcomes for colon cancer patients.
How similar studies have performed: While the specific role of Butyrophilins in colon cancer is not widely studied, similar approaches in identifying prognostic markers have shown promise in other cancer types.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient is older than 18 years old, * Signed participation consent, * Non-metastatic colon cancer immediately resectable or metastatic and liver synchronous for which it was decided a combined colic and liver surgery (metastatic patient at the outset) in multidisciplinary consultation meeting. * Performance Status (PS) 0 or 1 * affiliated to the social security or beneficiary Exclusion Criteria: * Rectal cancer, colon cancer recurrence * Emergency of colon cancer Surgery * History of inflammatory disease of the digestive tract (Crohn's disease or ulcerative colitis) * Patient who received neoadjuvant therapy other than chemotherapy * Patient treated with immune-suppressors or long-course corticosteroids \<12 months * Pregnant women or likely to be pregnant (without effective contraception) or breastfeeding, * Person in urgent situation, person under legal protection measure, or unable to express his / her consent, * Impossibility of submitting to the medical examination of the test for geographical, social or psychological reasons
Where this trial is running
Marseille
- Institut Paoli-Calmettes — Marseille, France (Recruiting)
Study contacts
- Study coordinator: Jihane PAKRADOUNI, PharmD,PhD
- Email: drci.up@ipc.unicancer.fr
- Phone: 04 91 22 37 78
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.